Patients with type 2 DM taking SGLT2 inhibitors as antihyperglycemic drugs are associated with a lower risk of all-cause mortality and arrhythmias compared with those without SGLT2 inhibitors prescription in real-world practice. The gene discussed is SLC5A2; the disease is cardiac arrhythmia.